Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD

NCT02209779 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02209779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02209779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2001
Completion date
Not reported
Enrollment
167 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid